These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16777817)

  • 1. The newborn drug development initiative.
    Giacoia GP; Birenbaum DL; Sachs HC; Mattison DR
    Pediatrics; 2006 Mar; 117(3 Pt 2):S1-8. PubMed ID: 16777817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborns and drug studies: the NICHD/FDA newborn drug development initiative.
    Giacoia GP; Mattison DR
    Clin Ther; 2005 Jun; 27(6):796-813. PubMed ID: 16117987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria supporting the study of drugs in the newborn.
    Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A
    Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative.
    Baer GR; Nelson RM;
    Clin Ther; 2006 Sep; 28(9):1399-407. PubMed ID: 17062312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug studies in newborns: a therapeutic imperative.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Perinatol; 2012 Mar; 39(1):11-23. PubMed ID: 22341533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of drugs used off-label in neonates: ethical issues and alternative study designs.
    Amin SB; McDermott MP; Shamoo AE
    Account Res; 2008; 15(3):168-87. PubMed ID: 18792537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
    Rivera DR; Hartzema AG
    Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
    Ren Z; Zajicek A
    Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context.
    Bleicher EW
    Food Drug Law J; 2009; 64(3):531-64. PubMed ID: 19999642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
    Giacoia GP; Mattison DR
    Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials in neonates: a therapeutic imperative.
    Ward RM; Kern SE
    Clin Pharmacol Ther; 2009 Dec; 86(6):585-7. PubMed ID: 19915600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities.
    Jacqz-Aigrain E
    Early Hum Dev; 2011 Mar; 87 Suppl 1():S27-30. PubMed ID: 21269785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular support in preterm infants.
    Evans JR; Lou Short B; Van Meurs K; Cheryl Sachs H
    Clin Ther; 2006 Sep; 28(9):1366-84. PubMed ID: 17062310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
    Breslow LH
    Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug labeling and exposure in neonates.
    Laughon MM; Avant D; Tripathi N; Hornik CP; Cohen-Wolkowiez M; Clark RH; Smith PB; Rodriguez W
    JAMA Pediatr; 2014 Feb; 168(2):130-6. PubMed ID: 24322269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaboration in Regulatory Science to Facilitate Therapeutic Development for Neonates.
    McCune SK; Mulugeta YA; Baer GR
    Curr Pharm Des; 2017; 23(38):5801-5804. PubMed ID: 28950828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.